Cancer
We’re investigating the biological basis of many solid and blood borne malignancies, advancing diagnosis, developing and trialing new therapies, and improving all aspects of the management of cancer including palliative care.
Testing the addition of immunotherapy in patients with endometrial cancer
The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.
Do you have an advanced solid tumour?
This study will investigate the use of a new medicine called AMT-151 which may be used in the future as a possible treatment for advanced solid tumours.
A new way of taking hormone tablets for patients with prostate cancer
The research study is testing a new way of taking hormone tablets for prostate cancer. The new method is called ‘adaptive therapy,’ also known as a pause/restart strategy.
Do you have newly diagnosed prostate cancer?
An Open-label, Randomised, Phase I, Multi-centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN)
Do you have ERpositive/HER2-negative early breast cancer?
Do you have ERpositive/HER2-negative early breast cancer?
A drug comparison for patients with newly diagnosed with metastatic hormone-sensitive prostate cancer
The purpose of this study is to compare the effects, good or bad of an investigational product, capivasertib added to standard treatments in patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) and your cancer has low levels of a protein called PTEN (or “PTEN deficiency”).
Assessing the effectiveness of DB-1303 in the treatment of HER2-low breast cancer
The purpose of this trial is to assess the effectiveness of DB-1303 in the treatment of hormone receptor positive, HER2-low breast cancer, compared to standard of care.
Do you have Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation?
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation.
Do you have newly diagnosed with advanced follicular lymphoma?
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
Do you have an advanced solid tumour?
This study will investigate the use of a new medicine called INX-315 which may be used in the future as a possible treatment for advanced solid tumours.